M. J. Biopharm Private Limited — Glibenclamide Exporter Profile
Indian Pharmaceutical Exporter · #2 for Glibenclamide · $375.5K export value · DGFT Verified
M. J. Biopharm Private Limited is the #2 Indian exporter of Glibenclamide with $375.5K in export value and 10 verified shipments. M. J. Biopharm Private Limited holds a 0.9% market share in Glibenclamide exports across 2 countries. The company exports 6 pharmaceutical products worth $22.4M across 4 therapeutic categories.
M. J. Biopharm Private Limited — Glibenclamide Export Profile: Buyers & Destinations
Where Does M. J. Biopharm Private Limited Export Glibenclamide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| RUSSIA | $314.6K | 8 | 94.4% |
| BOTSWANA | $18.7K | 2 | 5.6% |
M. J. Biopharm Private Limited exports Glibenclamide to 2 countries. The largest destination is RUSSIA accounting for 94.4% of M. J. Biopharm Private Limited's Glibenclamide shipments. These destinations reflect M. J. Biopharm Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Glibenclamide from M. J. Biopharm Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| PJSC PHARMSTANDARD-TOMSKHIMPHARM | RUSSIA | $164.6K | 5 |
| PJSC "PHARMSTANDARD-TOMSKHIMPHARM" | RUSSIA | $100.0K | 2 |
| M/S. PJSC "PHARMSTANDARD-TOMSKHIMPH | RUSSIA | $50.0K | 1 |
| PHARMA VISION (PTY) LTD | BOTSWANA | $18.7K | 2 |
M. J. Biopharm Private Limited supplies Glibenclamide to 4 buyers globally. The largest buyer is PJSC PHARMSTANDARD-TOMSKHIMPHARM (RUSSIA), followed by PJSC "PHARMSTANDARD-TOMSKHIMPHARM" (RUSSIA) and M/S. PJSC "PHARMSTANDARD-TOMSKHIMPH (RUSSIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Glibenclamide Export Value and How Much Does M. J. Biopharm Private Limited Contribute?
India exported $2.1M worth of Glibenclamide through 930 shipments from 194 suppliers to 100 countries, serving 335 buyers globally. M. J. Biopharm Private Limited contributes $375.5K to this total, accounting for 0.9% of India's Glibenclamide exports. M. J. Biopharm Private Limited ships Glibenclamide to 2 countries through 4 buyers.
What Is the Average Shipment Value for M. J. Biopharm Private Limited's Glibenclamide Exports?
M. J. Biopharm Private Limited's average Glibenclamide shipment value is $37.5K per consignment, based on 10 shipments totaling $375.5K. The largest destination is RUSSIA (94.4% of M. J. Biopharm Private Limited's Glibenclamide exports).
How Does M. J. Biopharm Private Limited Compare to Other Indian Glibenclamide Exporters?
M. J. Biopharm Private Limited ranks #2 among 194 Indian Glibenclamide exporters with a 0.9% market share. The top 3 exporters are MEDOPHARM ($420.3K), M. J. BIOPHARM PRIVATE LIMITED ($375.5K), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($274.9K). M. J. Biopharm Private Limited processed 10 shipments to 2 destination countries.
What Glibenclamide Formulations Does M. J. Biopharm Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| GLUCONORM TABLETS (GLIBENCLAMIDE 2.5 MG | $100.0K | 2 |
| GLUCONORM TABLETS GLIBENCLAMIDE 2.5 MG AND METFORMIN 400 MG TABLETS 119100 PACKS OF 20 TABS | $69.1K | 3 |
| GLUCONORM TABLETS [GLIBENCLAMIDE 2.5 MG | $50.0K | 1 |
| GLUCONORM TABLETS (GLIBENCLAMIDE 2.5 MGAND METFORMIN 400 MG TABLETS) 118600 PACKS OF 20 TABS | $50.0K | 1 |
| GLUCONORM TABLETS (GLIBENCLAMIDE 2.5 MGAND METFORMIN 400 MG TABLETS) 79200 PACKS OF 20 TABS | $45.5K | 1 |
| GLIBEX 5 (GLIBENCLAMIDE TABLETS BP 5MG) | $14.7K | 1 |
| GLIBEX 5 (GLIBENCLAMIDE TABLETS BP5MG) 9905 PACKS OF 10X10 TABS | $4.1K | 1 |
M. J. Biopharm Private Limited exports 7 distinct Glibenclamide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GLUCONORM TABLETS (GLIBENCLAMIDE 2.5 MG with 2 shipments worth $100.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does M. J. Biopharm Private Limited Compare to Nearest Glibenclamide Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | MEDOPHARM | $420.3K | 48 | 12 | $8.8K |
| 2 | M. J. BIOPHARM PRIVATE LIMITED ★ | $375.5K | 10 | 2 | $37.5K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $274.9K | 9 | 1 | $30.5K |
| 4 | CIPLA LIMITED | $235.1K | 27 | 1 | $8.7K |
M. J. Biopharm Private Limited ranks #2 among 194 Indian Glibenclamide exporters. Average shipment value of $37.5K compared to the market average of $11.0K. The closest competitors by value are MEDOPHARM and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Glibenclamide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 133 | 14.3% |
| NHAVA SHEVA SEA (INNSA1) | 130 | 14.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 99 | 10.6% |
| JNPT/ NHAVA SHEVA SEA | 61 | 6.6% |
| JNPT | 45 | 4.8% |
| Bombay Air | 33 | 3.5% |
| MUNDRA SEA | 32 | 3.4% |
| AHEMDABAD ICD | 27 | 2.9% |
Geopolitical & Trade Policy Impact on M. J. Biopharm Private Limited's Glibenclamide Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like M. J. Biopharm. Escalating tensions in the Middle East, particularly the Israel-Iran conflict, have disrupted key shipping routes through the Red Sea and the Suez Canal. Major carriers have suspended or rerouted shipments, leading to increased transit times and freight costs. This situation poses significant logistical hurdles for time-sensitive pharmaceutical exports. (livemint.com)
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the U.S. has also implemented policies favoring domestic manufacturing, such as the "Buy American" initiative, which could impact Indian companies' access to this lucrative market. (walterhealthcare.co.in)
In the European Union, stringent regulations like the Falsified Medicines Directive necessitate rigorous compliance from exporters. Indian companies must navigate these complex requirements to maintain market access, emphasizing the need for robust quality assurance systems. (ipa-india.org)
M. J. Biopharm Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practices (EU GMP) set stringent guidelines to ensure product safety and efficacy. Indian companies have faced challenges, including increased compliance costs and potential reductions in export volumes due to evolving regulations. (transdatanexus.com)
For M. J. Biopharm, maintaining adherence to these standards is crucial to sustain and expand its export markets. Investments in quality control, staff training, and infrastructure are essential to meet the evolving requirements and to build trust with international partners and regulatory bodies.
About M. J. Biopharm Private Limited
M. J. Biopharm Private Limited exports 6 products worth $22.4M. Beyond Glibenclamide, top products include Insulin, Meropenem, Imipenem, Ethambutol, Pyrazinamide. View the complete M. J. Biopharm Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Glibenclamide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Glibenclamide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: M. J. Biopharm Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 10 individual customs records matching M. J. Biopharm Private Limited exporting Glibenclamide, covering 7 formulations to 2 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 100+ countries, 335+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Glibenclamide Export Data from M. J. Biopharm Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for M. J. Biopharm Private Limited's Glibenclamide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
M. J. Biopharm Private Limited
Full Company Profile →
6 products · $22.4M total trade · 4 categories
Glibenclamide Stats
Company Overview
Top Products by M. J. Biopharm Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for M. J. Biopharm Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Glibenclamide. For current shipment-level data, contact TransData Nexus.